#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Understanding mechanisms of viral strategy to evade from host antiviral responses is critical for elucidation of the pathogenesis of CSFV infection .
3-1	15-28	Understanding	_	_	_	_
3-2	29-39	mechanisms	abstract[3]	new[3]	_	_
3-3	40-42	of	abstract[3]	new[3]	_	_
3-4	43-48	viral	abstract[3]|organization|abstract[5]	new[3]|new|new[5]	coref|coref|coref|coref	10-7|11-62[89_5]|10-7|11-62[89_5]
3-5	49-57	strategy	abstract[3]|abstract[5]	new[3]|new[5]	_	_
3-6	58-60	to	_	_	_	_
3-7	61-66	evade	_	_	_	_
3-8	67-71	from	_	_	_	_
3-9	72-76	host	abstract[6]	new[6]	coref	10-13[66_6]
3-10	77-86	antiviral	abstract[6]	new[6]	_	_
3-11	87-96	responses	abstract[6]	new[6]	_	_
3-12	97-99	is	_	_	_	_
3-13	100-108	critical	_	_	_	_
3-14	109-112	for	_	_	_	_
3-15	113-124	elucidation	abstract[7]	new[7]	_	_
3-16	125-127	of	abstract[7]	new[7]	_	_
3-17	128-131	the	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-18	132-144	pathogenesis	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-19	145-147	of	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-20	148-152	CSFV	abstract[7]|abstract[8]|object|abstract[10]	new[7]|new[8]|new|new[10]	coref|coref|coref|coref	5-1|11-14[73_10]|5-1|11-14[73_10]
3-21	153-162	infection	abstract[7]|abstract[8]|abstract[10]	new[7]|new[8]|new[10]	_	_
3-22	163-164	.	_	_	_	_

#Text=Type I IFNs represent one of the first lines of defense of the innate immune system and are produced rapidly upon recognition of viral factors by PRRs .
4-1	165-169	Type	abstract	new	coref	5-10
4-2	170-171	I	person	acc	ana	5-11
4-3	172-176	IFNs	abstract	new	coref	5-12
4-4	177-186	represent	_	_	_	_
4-5	187-190	one	abstract[14]	new[14]	_	_
4-6	191-193	of	abstract[14]	new[14]	_	_
4-7	194-197	the	abstract[14]|object[15]	new[14]|new[15]	coref	18-1[146_15]
4-8	198-203	first	abstract[14]|object[15]	new[14]|new[15]	_	_
4-9	204-209	lines	abstract[14]|object[15]	new[14]|new[15]	_	_
4-10	210-212	of	abstract[14]|object[15]	new[14]|new[15]	_	_
4-11	213-220	defense	abstract[14]|object[15]|abstract[16]	new[14]|new[15]|new[16]	_	_
4-12	221-223	of	abstract[14]|object[15]|abstract[16]	new[14]|new[15]|new[16]	_	_
4-13	224-227	the	abstract[14]|object[15]|abstract[16]|abstract[17]	new[14]|new[15]|new[16]|new[17]	_	_
4-14	228-234	innate	abstract[14]|object[15]|abstract[16]|abstract[17]	new[14]|new[15]|new[16]|new[17]	_	_
4-15	235-241	immune	abstract[14]|object[15]|abstract[16]|abstract[17]	new[14]|new[15]|new[16]|new[17]	_	_
4-16	242-248	system	abstract[14]|object[15]|abstract[16]|abstract[17]	new[14]|new[15]|new[16]|new[17]	_	_
4-17	249-252	and	_	_	_	_
4-18	253-256	are	_	_	_	_
4-19	257-265	produced	_	_	_	_
4-20	266-273	rapidly	_	_	_	_
4-21	274-278	upon	_	_	_	_
4-22	279-290	recognition	event[18]	new[18]	_	_
4-23	291-293	of	event[18]	new[18]	_	_
4-24	294-299	viral	event[18]|abstract[19]	new[18]|new[19]	_	_
4-25	300-307	factors	event[18]|abstract[19]	new[18]|new[19]	_	_
4-26	308-310	by	event[18]|abstract[19]	new[18]|new[19]	_	_
4-27	311-315	PRRs	event[18]|abstract[19]|abstract	new[18]|new[19]|new	_	_
4-28	316-317	.	_	_	_	_

#Text=CSFV is known to interfere with the generation of type I IFNs by inducing proteasomal degradation of IRF3 .
5-1	318-322	CSFV	object	giv	coref	7-12
5-2	323-325	is	_	_	_	_
5-3	326-331	known	_	_	_	_
5-4	332-334	to	_	_	_	_
5-5	335-344	interfere	_	_	_	_
5-6	345-349	with	_	_	_	_
5-7	350-353	the	abstract[22]	new[22]	_	_
5-8	354-364	generation	abstract[22]	new[22]	_	_
5-9	365-367	of	abstract[22]	new[22]	_	_
5-10	368-372	type	abstract[22]|abstract	new[22]|giv	coref	6-1[29_0]
5-11	373-374	I	person	giv	ana	16-14
5-12	375-379	IFNs	abstract	giv	coref	8-15
5-13	380-382	by	_	_	_	_
5-14	383-391	inducing	_	_	_	_
5-15	392-403	proteasomal	animal|abstract[27]	new|new[27]	_	_
5-16	404-415	degradation	abstract[27]	new[27]	_	_
5-17	416-418	of	abstract[27]	new[27]	_	_
5-18	419-423	IRF3	abstract[27]|object	new[27]|new	coref	25-16
5-19	424-425	.	_	_	_	_

#Text=Type III IFNs play a critical role in antiviral innate immunity in mucosal epithelial cells .
6-1	426-430	Type	abstract[29]	giv[29]	coref	7-14[0_29]
6-2	431-434	III	abstract[29]	giv[29]	_	_
6-3	435-439	IFNs	abstract[29]	giv[29]	_	_
6-4	440-444	play	_	_	_	_
6-5	445-446	a	abstract[30]	new[30]	_	_
6-6	447-455	critical	abstract[30]	new[30]	_	_
6-7	456-460	role	abstract[30]	new[30]	_	_
6-8	461-463	in	abstract[30]	new[30]	_	_
6-9	464-473	antiviral	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-10	474-480	innate	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-11	481-489	immunity	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-12	490-492	in	abstract[30]|abstract[31]	new[30]|new[31]	_	_
6-13	493-500	mucosal	abstract[30]|abstract[31]|place[32]	new[30]|new[31]|new[32]	coref	11-46[85_32]
6-14	501-511	epithelial	abstract[30]|abstract[31]|place[32]	new[30]|new[31]|new[32]	_	_
6-15	512-517	cells	abstract[30]|abstract[31]|place[32]	new[30]|new[31]|new[32]	_	_
6-16	518-519	.	_	_	_	_

#Text=However , little information is available as to whether and how CSFV modulates type III IFN response .
7-1	520-527	However	_	_	_	_
7-2	528-529	,	_	_	_	_
7-3	530-536	little	abstract[33]	new[33]	_	_
7-4	537-548	information	abstract[33]	new[33]	_	_
7-5	549-551	is	_	_	_	_
7-6	552-561	available	_	_	_	_
7-7	562-564	as	_	_	_	_
7-8	565-567	to	_	_	_	_
7-9	568-575	whether	_	_	_	_
7-10	576-579	and	_	_	_	_
7-11	580-583	how	_	_	_	_
7-12	584-588	CSFV	object	giv	coref	8-10
7-13	589-598	modulates	_	_	_	_
7-14	599-603	type	abstract	giv	coref	8-12[42_0]
7-15	604-607	III	abstract[37]	new[37]	coref	11-25[77_37]
7-16	608-611	IFN	organization|abstract[37]	new|new[37]	coref	20-12
7-17	612-620	response	abstract[37]	new[37]	_	_
7-18	621-622	.	_	_	_	_

#Text=The present study demonstrates that the Npro protein of CSFV inhibited IRF1-mediated type III IFNs production by down-regulation of IRF1 expression and blockage of its nuclear translocation .
8-1	623-626	The	event[38]	new[38]	coref	9-30[59_38]
8-2	627-634	present	event[38]	new[38]	_	_
8-3	635-640	study	event[38]	new[38]	_	_
8-4	641-653	demonstrates	_	_	_	_
8-5	654-658	that	_	_	_	_
8-6	659-662	the	substance[40]	new[40]	ana	8-25[0_40]
8-7	663-667	Npro	object|substance[40]	new|new[40]	coref	19-29
8-8	668-675	protein	substance[40]	new[40]	_	_
8-9	676-678	of	substance[40]	new[40]	_	_
8-10	679-683	CSFV	substance[40]|object	new[40]|giv	coref	9-15[56_0]
8-11	684-693	inhibited	_	_	_	_
8-12	694-707	IRF1-mediated	abstract[42]	giv[42]	appos	8-14[44_42]
8-13	708-712	type	abstract[42]	giv[42]	_	_
8-14	713-716	III	abstract[44]	giv[44]	coref	10-12[64_44]
8-15	717-721	IFNs	object|abstract[44]	giv|giv[44]	coref	10-14
8-16	722-732	production	abstract[44]	giv[44]	_	_
8-17	733-735	by	_	_	_	_
8-18	736-751	down-regulation	abstract[45]	new[45]	_	_
8-19	752-754	of	abstract[45]	new[45]	_	_
8-20	755-759	IRF1	abstract[45]|abstract|abstract[47]	new[45]|new|new[47]	coref|coref	27-1|27-1
8-21	760-770	expression	abstract[45]|abstract[47]	new[45]|new[47]	_	_
8-22	771-774	and	abstract[45]	new[45]	_	_
8-23	775-783	blockage	abstract[45]|object[48]	new[45]|new[48]	_	_
8-24	784-786	of	abstract[45]|object[48]	new[45]|new[48]	_	_
8-25	787-790	its	abstract[45]|object[48]|substance|abstract[50]	new[45]|new[48]|giv|new[50]	coref|coref	19-28[167_0]|19-28[167_0]
8-26	791-798	nuclear	abstract[45]|object[48]|abstract[50]	new[45]|new[48]|new[50]	_	_
8-27	799-812	translocation	abstract[45]|object[48]|abstract[50]	new[45]|new[48]|new[50]	_	_
8-28	813-814	.	_	_	_	_

#Text=The Npro-deleted mutant showed similar growth kinetics to its parental strain , indicating that CSFV Npro does not alter the replication in cell culture , which is consistent with the previous study .
9-1	815-818	The	object[51]	new[51]	ana	9-9[0_51]
9-2	819-831	Npro-deleted	object[51]	new[51]	_	_
9-3	832-838	mutant	object[51]	new[51]	_	_
9-4	839-845	showed	_	_	_	_
9-5	846-853	similar	abstract[53]	new[53]	_	_
9-6	854-860	growth	abstract|abstract[53]	new|new[53]	_	_
9-7	861-869	kinetics	abstract[53]	new[53]	_	_
9-8	870-872	to	abstract[53]	new[53]	_	_
9-9	873-876	its	abstract[53]|object|object[55]	new[53]|giv|new[55]	coref|coref|coref|coref	19-4[157_0]|19-22[165_55]|19-4[157_0]|19-22[165_55]
9-10	877-885	parental	abstract[53]|object[55]	new[53]|new[55]	_	_
9-11	886-892	strain	abstract[53]|object[55]	new[53]|new[55]	_	_
9-12	893-894	,	_	_	_	_
9-13	895-905	indicating	_	_	_	_
9-14	906-910	that	_	_	_	_
9-15	911-915	CSFV	object[56]	giv[56]	coref	11-37[0_56]
9-16	916-920	Npro	object[56]	giv[56]	_	_
9-17	921-925	does	_	_	_	_
9-18	926-929	not	_	_	_	_
9-19	930-935	alter	_	_	_	_
9-20	936-939	the	abstract[57]	new[57]	_	_
9-21	940-951	replication	abstract[57]	new[57]	_	_
9-22	952-954	in	abstract[57]	new[57]	_	_
9-23	955-959	cell	abstract[57]|abstract[58]	new[57]|new[58]	_	_
9-24	960-967	culture	abstract[57]|abstract[58]	new[57]|new[58]	_	_
9-25	968-969	,	_	_	_	_
9-26	970-975	which	_	_	_	_
9-27	976-978	is	_	_	_	_
9-28	979-989	consistent	_	_	_	_
9-29	990-994	with	_	_	_	_
9-30	995-998	the	event[59]	giv[59]	coref	17-10[145_59]
9-31	999-1007	previous	event[59]	giv[59]	_	_
9-32	1008-1013	study	event[59]	giv[59]	_	_
9-33	1014-1015	.	_	_	_	_

#Text=Some viruses have evolved to encode viral antagonists for evasion of type III IFNs responses .
10-1	1016-1020	Some	animal[60]	new[60]	coref	27-8[238_60]
10-2	1021-1028	viruses	animal[60]	new[60]	_	_
10-3	1029-1033	have	_	_	_	_
10-4	1034-1041	evolved	_	_	_	_
10-5	1042-1044	to	_	_	_	_
10-6	1045-1051	encode	_	_	_	_
10-7	1052-1057	viral	organization|person[62]	giv|new[62]	coref|coref	29-11|29-11
10-8	1058-1069	antagonists	person[62]	new[62]	_	_
10-9	1070-1073	for	_	_	_	_
10-10	1074-1081	evasion	abstract[63]	new[63]	_	_
10-11	1082-1084	of	abstract[63]	new[63]	_	_
10-12	1085-1089	type	abstract[63]|abstract[64]	new[63]|giv[64]	coref	11-8[0_64]
10-13	1090-1093	III	abstract[63]|abstract[64]|abstract[66]	new[63]|giv[64]|giv[66]	_	_
10-14	1094-1098	IFNs	abstract[63]|abstract[64]|abstract|abstract[66]	new[63]|giv[64]|giv|giv[66]	coref	12-9
10-15	1099-1108	responses	abstract[63]|abstract[64]|abstract[66]	new[63]|giv[64]|giv[66]	_	_
10-16	1109-1110	.	_	_	_	_

#Text=Reid et al showed the induction of type III IFNs in pDCs upon BVDV infection , and type III IFNs contributed to suppression of cellular immune response during BVDV infection . Cai et al shows that CSFV induced the expression of type III IFNs in PK-15 cells , but with a limited level of increase , suggesting that CSFV might have a strategy to suppress expression of type III IFNs .
11-1	1111-1115	Reid	person	new	_	_
11-2	1116-1118	et	_	_	_	_
11-3	1119-1121	al	_	_	_	_
11-4	1122-1128	showed	_	_	_	_
11-5	1129-1132	the	abstract[68]	new[68]	_	_
11-6	1133-1142	induction	abstract[68]	new[68]	_	_
11-7	1143-1145	of	abstract[68]	new[68]	_	_
11-8	1146-1150	type	abstract[68]|abstract	new[68]|giv	appos	11-9[70_0]
11-9	1151-1154	III	abstract[70]	giv[70]	coref	11-18[74_70]
11-10	1155-1159	IFNs	abstract[70]	giv[70]	_	_
11-11	1160-1162	in	_	_	_	_
11-12	1163-1167	pDCs	place[71]	new[71]	_	_
11-13	1168-1172	upon	place[71]	new[71]	_	_
11-14	1173-1177	BVDV	place[71]|object|abstract[73]	new[71]|new|giv[73]	coref|coref	11-29[78_73]|11-29[78_73]
11-15	1178-1187	infection	place[71]|abstract[73]	new[71]|giv[73]	_	_
11-16	1188-1189	,	_	_	_	_
11-17	1190-1193	and	_	_	_	_
11-18	1194-1198	type	abstract[74]	giv[74]	coref	11-42[0_74]
11-19	1199-1202	III	abstract[74]	giv[74]	_	_
11-20	1203-1207	IFNs	abstract[74]	giv[74]	_	_
11-21	1208-1219	contributed	_	_	_	_
11-22	1220-1222	to	_	_	_	_
11-23	1223-1234	suppression	abstract[75]	new[75]	_	_
11-24	1235-1237	of	abstract[75]	new[75]	_	_
11-25	1238-1246	cellular	abstract[75]|abstract[77]	new[75]|giv[77]	_	_
11-26	1247-1253	immune	abstract[75]|abstract|abstract[77]	new[75]|new|giv[77]	_	_
11-27	1254-1262	response	abstract[75]|abstract[77]	new[75]|giv[77]	_	_
11-28	1263-1269	during	abstract[75]|abstract[77]	new[75]|giv[77]	_	_
11-29	1270-1274	BVDV	abstract[75]|abstract[77]|abstract[78]	new[75]|giv[77]|giv[78]	coref	12-12[100_78]
11-30	1275-1284	infection	abstract[75]|abstract[77]|abstract[78]	new[75]|giv[77]|giv[78]	_	_
11-31	1285-1286	.	_	_	_	_
11-32	1287-1290	Cai	person	new	coref	12-38
11-33	1291-1293	et	_	_	_	_
11-34	1294-1296	al	_	_	_	_
11-35	1297-1302	shows	_	_	_	_
11-36	1303-1307	that	_	_	_	_
11-37	1308-1312	CSFV	object	giv	coref	11-59
11-38	1313-1320	induced	_	_	_	_
11-39	1321-1324	the	abstract[81]	new[81]	_	_
11-40	1325-1335	expression	abstract[81]	new[81]	_	_
11-41	1336-1338	of	abstract[81]	new[81]	_	_
11-42	1339-1343	type	abstract[81]|abstract	new[81]|giv	appos	11-43[83_0]
11-43	1344-1347	III	abstract[83]	giv[83]	coref	11-68[0_83]
11-44	1348-1352	IFNs	abstract[83]	giv[83]	_	_
11-45	1353-1355	in	_	_	_	_
11-46	1356-1361	PK-15	time|place[85]	new|giv[85]	coref|coref	12-15[102_85]|12-15[102_85]
11-47	1362-1367	cells	place[85]	giv[85]	_	_
11-48	1368-1369	,	_	_	_	_
11-49	1370-1373	but	_	_	_	_
11-50	1374-1378	with	_	_	_	_
11-51	1379-1380	a	abstract[86]	new[86]	coref	12-19[104_86]
11-52	1381-1388	limited	abstract[86]	new[86]	_	_
11-53	1389-1394	level	abstract[86]	new[86]	_	_
11-54	1395-1397	of	abstract[86]	new[86]	_	_
11-55	1398-1406	increase	abstract[86]|abstract	new[86]|new	_	_
11-56	1407-1408	,	_	_	_	_
11-57	1409-1419	suggesting	_	_	_	_
11-58	1420-1424	that	_	_	_	_
11-59	1425-1429	CSFV	object	giv	coref	14-2
11-60	1430-1435	might	_	_	_	_
11-61	1436-1440	have	_	_	_	_
11-62	1441-1442	a	abstract[89]	giv[89]	_	_
11-63	1443-1451	strategy	abstract[89]	giv[89]	_	_
11-64	1452-1454	to	_	_	_	_
11-65	1455-1463	suppress	_	_	_	_
11-66	1464-1474	expression	abstract[90]	new[90]	coref	19-35[168_90]
11-67	1475-1477	of	abstract[90]	new[90]	_	_
11-68	1478-1482	type	abstract[90]|abstract	new[90]|giv	appos	11-69[92_0]
11-69	1483-1486	III	abstract[92]	giv[92]	coref	12-7[0_92]
11-70	1487-1491	IFNs	abstract[92]	giv[92]	_	_
11-71	1492-1493	.	_	_	_	_

#Text=We also found limited up-regulation of type III IFNs transcription upon wtCSFV infection in IPEC-J2 cells , though the transcription level peaked at 24 hpi and decreased thereafter , which is different from the results shown by Cai et al that the mRNA level of IFN-λ1 and IFN-λ3 induced by wtCSFV peaked at 36 and 48 hpi , respectively .
12-1	1494-1496	We	person	acc	ana	13-1
12-2	1497-1501	also	_	_	_	_
12-3	1502-1507	found	_	_	_	_
12-4	1508-1515	limited	abstract[94]	new[94]	_	_
12-5	1516-1529	up-regulation	abstract[94]	new[94]	_	_
12-6	1530-1532	of	abstract[94]	new[94]	_	_
12-7	1533-1537	type	abstract[94]|abstract|abstract[96]	new[94]|giv|new[96]	coref|coref|coref|coref	16-6|20-9[173_96]|16-6|20-9[173_96]
12-8	1538-1541	III	abstract[94]|abstract[96]|abstract[98]	new[94]|new[96]|new[98]	coref	12-20[0_98]
12-9	1542-1546	IFNs	abstract[94]|abstract[96]|abstract|abstract[98]	new[94]|new[96]|giv|new[98]	coref	16-15
12-10	1547-1560	transcription	abstract[94]|abstract[96]|abstract[98]	new[94]|new[96]|new[98]	_	_
12-11	1561-1565	upon	abstract[94]|abstract[96]|abstract[98]	new[94]|new[96]|new[98]	_	_
12-12	1566-1572	wtCSFV	abstract[94]|abstract[96]|abstract[98]|object|abstract[100]	new[94]|new[96]|new[98]|new|giv[100]	coref|coref|coref|coref	12-51|15-20[0_100]|12-51|15-20[0_100]
12-13	1573-1582	infection	abstract[94]|abstract[96]|abstract[98]|abstract[100]	new[94]|new[96]|new[98]|giv[100]	_	_
12-14	1583-1585	in	abstract[94]|abstract[96]|abstract[98]|abstract[100]	new[94]|new[96]|new[98]|giv[100]	_	_
12-15	1586-1593	IPEC-J2	abstract[94]|abstract[96]|abstract[98]|abstract[100]|substance|place[102]	new[94]|new[96]|new[98]|giv[100]|new|giv[102]	coref|coref|coref|coref	15-2|15-7[128_102]|15-2|15-7[128_102]
12-16	1594-1599	cells	abstract[94]|abstract[96]|abstract[98]|abstract[100]|place[102]	new[94]|new[96]|new[98]|giv[100]|giv[102]	_	_
12-17	1600-1601	,	_	_	_	_
12-18	1602-1608	though	_	_	_	_
12-19	1609-1612	the	abstract[104]	giv[104]	_	_
12-20	1613-1626	transcription	abstract|abstract[104]	giv|giv[104]	coref	19-8[158_0]
12-21	1627-1632	level	abstract[104]	giv[104]	_	_
12-22	1633-1639	peaked	_	_	_	_
12-23	1640-1642	at	_	_	_	_
12-24	1643-1645	24	quantity[105]	new[105]	_	_
12-25	1646-1649	hpi	quantity[105]	new[105]	_	_
12-26	1650-1653	and	_	_	_	_
12-27	1654-1663	decreased	_	_	_	_
12-28	1664-1674	thereafter	_	_	_	_
12-29	1675-1676	,	_	_	_	_
12-30	1677-1682	which	_	_	_	_
12-31	1683-1685	is	_	_	_	_
12-32	1686-1695	different	_	_	_	_
12-33	1696-1700	from	_	_	_	_
12-34	1701-1704	the	abstract[106]	new[106]	coref	24-1[212_106]
12-35	1705-1712	results	abstract[106]	new[106]	_	_
12-36	1713-1718	shown	_	_	_	_
12-37	1719-1721	by	_	_	_	_
12-38	1722-1725	Cai	person	giv	_	_
12-39	1726-1728	et	_	_	_	_
12-40	1729-1731	al	_	_	_	_
12-41	1732-1736	that	_	_	_	_
12-42	1737-1740	the	abstract[109]	new[109]	_	_
12-43	1741-1745	mRNA	place|abstract[109]	new|new[109]	coref	22-13
12-44	1746-1751	level	abstract[109]	new[109]	_	_
12-45	1752-1754	of	abstract[109]	new[109]	_	_
12-46	1755-1761	IFN-λ1	abstract[109]|abstract	new[109]|new	_	_
12-47	1762-1765	and	abstract[109]	new[109]	_	_
12-48	1766-1772	IFN-λ3	abstract[109]|abstract	new[109]|new	coref	23-16
12-49	1773-1780	induced	_	_	_	_
12-50	1781-1783	by	_	_	_	_
12-51	1784-1790	wtCSFV	abstract	giv	coref	21-4
12-52	1791-1797	peaked	_	_	_	_
12-53	1798-1800	at	_	_	_	_
12-54	1801-1803	36	quantity	new	_	_
12-55	1804-1807	and	_	_	_	_
12-56	1808-1810	48	quantity[114]	new[114]	coref	19-19[163_114]
12-57	1811-1814	hpi	quantity[114]	new[114]	_	_
12-58	1815-1816	,	_	_	_	_
12-59	1817-1829	respectively	_	_	_	_
12-60	1830-1831	.	_	_	_	_

#Text=We speculate that the difference might be due to different cell types used .
13-1	1832-1834	We	person	giv	ana	19-1
13-2	1835-1844	speculate	_	_	_	_
13-3	1845-1849	that	_	_	_	_
13-4	1850-1853	the	abstract[116]	new[116]	_	_
13-5	1854-1864	difference	abstract[116]	new[116]	_	_
13-6	1865-1870	might	_	_	_	_
13-7	1871-1873	be	_	_	_	_
13-8	1874-1877	due	_	_	_	_
13-9	1878-1880	to	_	_	_	_
13-10	1881-1890	different	abstract[118]	new[118]	_	_
13-11	1891-1895	cell	object|abstract[118]	new|new[118]	coref	14-8
13-12	1896-1901	types	abstract[118]	new[118]	_	_
13-13	1902-1906	used	_	_	_	_
13-14	1907-1908	.	_	_	_	_

#Text=Because CSFV causes enteric pathologies , a cell line from the intestines could be a good choice .
14-1	1909-1916	Because	_	_	_	_
14-2	1917-1921	CSFV	substance	giv	coref	18-24
14-3	1922-1928	causes	_	_	_	_
14-4	1929-1936	enteric	abstract[120]	new[120]	_	_
14-5	1937-1948	pathologies	abstract[120]	new[120]	_	_
14-6	1949-1950	,	_	_	_	_
14-7	1951-1952	a	abstract[122]	new[122]	coref	14-15[124_122]
14-8	1953-1957	cell	object|abstract[122]	giv|new[122]	coref	15-3
14-9	1958-1962	line	abstract[122]	new[122]	_	_
14-10	1963-1967	from	abstract[122]	new[122]	_	_
14-11	1968-1971	the	abstract[122]|place[123]	new[122]|new[123]	_	_
14-12	1972-1982	intestines	abstract[122]|place[123]	new[122]|new[123]	_	_
14-13	1983-1988	could	_	_	_	_
14-14	1989-1991	be	_	_	_	_
14-15	1992-1993	a	abstract[124]	giv[124]	coref	15-1[127_124]
14-16	1994-1998	good	abstract[124]	giv[124]	_	_
14-17	1999-2005	choice	abstract[124]	giv[124]	_	_
14-18	2006-2007	.	_	_	_	_

#Text=The IPEC-J2 cell line was from non-transformed cells collected from the jejunum of a neonatal piglet and suitable for infection studies for enteropathogens .
15-1	2008-2011	The	abstract[127]	giv[127]	coref	17-3[144_127]
15-2	2012-2019	IPEC-J2	time|abstract[127]	giv|giv[127]	coref	16-1
15-3	2020-2024	cell	object|abstract[127]	giv|giv[127]	coref	17-5
15-4	2025-2029	line	abstract[127]	giv[127]	_	_
15-5	2030-2033	was	_	_	_	_
15-6	2034-2038	from	_	_	_	_
15-7	2039-2054	non-transformed	place[128]	giv[128]	coref	19-14[161_128]
15-8	2055-2060	cells	place[128]	giv[128]	_	_
15-9	2061-2070	collected	_	_	_	_
15-10	2071-2075	from	_	_	_	_
15-11	2076-2079	the	object[129]	new[129]	_	_
15-12	2080-2087	jejunum	object[129]	new[129]	_	_
15-13	2088-2090	of	object[129]	new[129]	_	_
15-14	2091-2092	a	object[129]|animal[130]	new[129]|new[130]	_	_
15-15	2093-2101	neonatal	object[129]|animal[130]	new[129]|new[130]	_	_
15-16	2102-2108	piglet	object[129]|animal[130]	new[129]|new[130]	_	_
15-17	2109-2112	and	object[129]	new[129]	_	_
15-18	2113-2121	suitable	object[129]	new[129]	_	_
15-19	2122-2125	for	_	_	_	_
15-20	2126-2135	infection	abstract|event[132]	giv|new[132]	coref|coref	23-1[201_0]|23-1[201_0]
15-21	2136-2143	studies	event[132]	new[132]	_	_
15-22	2144-2147	for	_	_	_	_
15-23	2148-2163	enteropathogens	abstract	new	_	_
15-24	2164-2165	.	_	_	_	_

#Text=IPEC-J2 exhibited robust expression of type III IFNs with a relatively lower type I IFNs response .
16-1	2166-2173	IPEC-J2	organization	giv	coref	17-4
16-2	2174-2183	exhibited	_	_	_	_
16-3	2184-2190	robust	abstract[135]	new[135]	_	_
16-4	2191-2201	expression	abstract[135]	new[135]	_	_
16-5	2202-2204	of	abstract[135]	new[135]	_	_
16-6	2205-2209	type	abstract[135]|abstract	new[135]|giv	coref	16-7[137_0]
16-7	2210-2213	III	abstract[137]	giv[137]	coref	16-10[138_137]
16-8	2214-2218	IFNs	abstract[137]	giv[137]	_	_
16-9	2219-2223	with	_	_	_	_
16-10	2224-2225	a	abstract[138]	giv[138]	appos	16-15[141_138]
16-11	2226-2236	relatively	abstract[138]	giv[138]	_	_
16-12	2237-2242	lower	abstract[138]	giv[138]	_	_
16-13	2243-2247	type	abstract[138]	giv[138]	_	_
16-14	2248-2249	I	person	giv	ana	20-11
16-15	2250-2254	IFNs	organization|abstract[141]	giv|giv[141]	coref|coref|coref|coref	18-26[0_141]|19-12|18-26[0_141]|19-12
16-16	2255-2263	response	abstract[141]	giv[141]	_	_
16-17	2264-2265	.	_	_	_	_

#Text=Thus , the IPEC-J2 cell line was chosen in this study .
17-1	2266-2270	Thus	_	_	_	_
17-2	2271-2272	,	_	_	_	_
17-3	2273-2276	the	abstract[144]	giv[144]	_	_
17-4	2277-2284	IPEC-J2	time|abstract[144]	giv|giv[144]	coref	19-14
17-5	2285-2289	cell	object|abstract[144]	giv|giv[144]	_	_
17-6	2290-2294	line	abstract[144]	giv[144]	_	_
17-7	2295-2298	was	_	_	_	_
17-8	2299-2305	chosen	_	_	_	_
17-9	2306-2308	in	_	_	_	_
17-10	2309-2313	this	event[145]	giv[145]	_	_
17-11	2314-2319	study	event[145]	giv[145]	_	_
17-12	2320-2321	.	_	_	_	_

#Text=Cell lines or primary cultures from other intestinal areas or from adult pigs could be approached for further investigation of the interactions between CSFV and type III IFNs .
18-1	2322-2326	Cell	object[146]	giv[146]	_	_
18-2	2327-2332	lines	object[146]	giv[146]	_	_
18-3	2333-2335	or	object[146]	giv[146]	_	_
18-4	2336-2343	primary	object[146]|abstract[147]	giv[146]|new[147]	_	_
18-5	2344-2352	cultures	object[146]|abstract[147]	giv[146]|new[147]	_	_
18-6	2353-2357	from	object[146]|abstract[147]	giv[146]|new[147]	_	_
18-7	2358-2363	other	object[146]|abstract[147]|place[148]	giv[146]|new[147]|new[148]	_	_
18-8	2364-2374	intestinal	object[146]|abstract[147]|place[148]	giv[146]|new[147]|new[148]	_	_
18-9	2375-2380	areas	object[146]|abstract[147]|place[148]	giv[146]|new[147]|new[148]	_	_
18-10	2381-2383	or	_	_	_	_
18-11	2384-2388	from	_	_	_	_
18-12	2389-2394	adult	animal[149]	new[149]	_	_
18-13	2395-2399	pigs	animal[149]	new[149]	_	_
18-14	2400-2405	could	_	_	_	_
18-15	2406-2408	be	_	_	_	_
18-16	2409-2419	approached	_	_	_	_
18-17	2420-2423	for	_	_	_	_
18-18	2424-2431	further	abstract[150]	new[150]	_	_
18-19	2432-2445	investigation	abstract[150]	new[150]	_	_
18-20	2446-2448	of	abstract[150]	new[150]	_	_
18-21	2449-2452	the	abstract[150]|abstract[151]	new[150]|new[151]	_	_
18-22	2453-2465	interactions	abstract[150]|abstract[151]	new[150]|new[151]	_	_
18-23	2466-2473	between	abstract[150]|abstract[151]	new[150]|new[151]	_	_
18-24	2474-2478	CSFV	abstract[150]|abstract[151]|object	new[150]|new[151]|giv	coref	20-2[171_0]
18-25	2479-2482	and	abstract[150]|abstract[151]	new[150]|new[151]	_	_
18-26	2483-2487	type	abstract[150]|abstract[151]|abstract	new[150]|new[151]|giv	coref	18-27[154_0]
18-27	2488-2491	III	abstract[150]|abstract[151]|abstract[154]	new[150]|new[151]|giv[154]	coref	19-37[0_154]
18-28	2492-2496	IFNs	abstract[150]|abstract[151]|abstract[154]	new[150]|new[151]|giv[154]	_	_
18-29	2497-2498	.	_	_	_	_

#Text=We found that the ∆Npro mutant induced significantly higher transcription of IFNs in IPEC-J2 cells from 24 to 48 hpi than its parental strain , suggesting that the Npro protein might be antagonistic to expression of type III IFNs .
19-1	2499-2501	We	person	giv	ana	20-15
19-2	2502-2507	found	_	_	_	_
19-3	2508-2512	that	_	_	_	_
19-4	2513-2516	the	object[157]	giv[157]	_	_
19-5	2517-2522	∆Npro	abstract|object[157]	new|giv[157]	_	_
19-6	2523-2529	mutant	object[157]	giv[157]	_	_
19-7	2530-2537	induced	_	_	_	_
19-8	2538-2551	significantly	abstract[158]	giv[158]	ana	19-22[0_158]
19-9	2552-2558	higher	abstract[158]	giv[158]	_	_
19-10	2559-2572	transcription	abstract[158]	giv[158]	_	_
19-11	2573-2575	of	abstract[158]	giv[158]	_	_
19-12	2576-2580	IFNs	abstract[158]|abstract	giv[158]|giv	coref	24-13
19-13	2581-2583	in	abstract[158]	giv[158]	_	_
19-14	2584-2591	IPEC-J2	abstract[158]|substance|place[161]	giv[158]|giv|giv[161]	coref|coref|coref|coref	21-16|21-16[189_161]|21-16|21-16[189_161]
19-15	2592-2597	cells	abstract[158]|place[161]	giv[158]|giv[161]	_	_
19-16	2598-2602	from	abstract[158]|place[161]	giv[158]|giv[161]	_	_
19-17	2603-2605	24	abstract[158]|place[161]|quantity	giv[158]|giv[161]|new	_	_
19-18	2606-2608	to	_	_	_	_
19-19	2609-2611	48	quantity[163]	giv[163]	_	_
19-20	2612-2615	hpi	quantity[163]	giv[163]	_	_
19-21	2616-2620	than	quantity[163]	giv[163]	_	_
19-22	2621-2624	its	quantity[163]|abstract|object[165]	giv[163]|giv|giv[165]	_	_
19-23	2625-2633	parental	quantity[163]|object[165]	giv[163]|giv[165]	_	_
19-24	2634-2640	strain	quantity[163]|object[165]	giv[163]|giv[165]	_	_
19-25	2641-2642	,	_	_	_	_
19-26	2643-2653	suggesting	_	_	_	_
19-27	2654-2658	that	_	_	_	_
19-28	2659-2662	the	substance[167]	giv[167]	_	_
19-29	2663-2667	Npro	object|substance[167]	giv|giv[167]	coref	20-18
19-30	2668-2675	protein	substance[167]	giv[167]	_	_
19-31	2676-2681	might	_	_	_	_
19-32	2682-2684	be	_	_	_	_
19-33	2685-2697	antagonistic	_	_	_	_
19-34	2698-2700	to	_	_	_	_
19-35	2701-2711	expression	abstract[168]	giv[168]	coref	33-31[296_168]
19-36	2712-2714	of	abstract[168]	giv[168]	_	_
19-37	2715-2719	type	abstract[168]|abstract	giv[168]|giv	coref	19-38[170_0]
19-38	2720-2723	III	abstract[170]	giv[170]	coref	20-9[172_170]
19-39	2724-2728	IFNs	abstract[170]	giv[170]	_	_
19-40	2729-2730	.	_	_	_	_

#Text=Because CSFV Npro has been found to subvert the type I IFN response , we speculated if Npro might have similar effect on type III IFNs .
20-1	2731-2738	Because	_	_	_	_
20-2	2739-2743	CSFV	abstract[171]	giv[171]	coref	24-5[0_171]
20-3	2744-2748	Npro	abstract[171]	giv[171]	_	_
20-4	2749-2752	has	_	_	_	_
20-5	2753-2757	been	_	_	_	_
20-6	2758-2763	found	_	_	_	_
20-7	2764-2766	to	_	_	_	_
20-8	2767-2774	subvert	_	_	_	_
20-9	2775-2778	the	abstract[172]|abstract[173]	giv[172]|giv[173]	coref|coref	20-12[176_172]|20-12[176_172]
20-10	2779-2783	type	abstract[172]|abstract[173]	giv[172]|giv[173]	_	_
20-11	2784-2785	I	abstract[173]|person	giv[173]|giv	ana	25-12
20-12	2786-2789	IFN	abstract[173]|organization|abstract[176]	giv[173]|giv|giv[176]	coref|coref	20-24[0_176]|20-24[0_176]
20-13	2790-2798	response	abstract[173]|abstract[176]	giv[173]|giv[176]	_	_
20-14	2799-2800	,	_	_	_	_
20-15	2801-2803	we	person	giv	ana	21-1
20-16	2804-2814	speculated	_	_	_	_
20-17	2815-2817	if	_	_	_	_
20-18	2818-2822	Npro	substance	giv	coref	21-19
20-19	2823-2828	might	_	_	_	_
20-20	2829-2833	have	_	_	_	_
20-21	2834-2841	similar	abstract[179]	new[179]	coref	21-22[192_179]
20-22	2842-2848	effect	abstract[179]	new[179]	_	_
20-23	2849-2851	on	abstract[179]	new[179]	_	_
20-24	2852-2856	type	abstract[179]|abstract	new[179]|giv	coref	20-25[181_0]
20-25	2857-2860	III	abstract[181]	giv[181]	coref	21-13[187_181]
20-26	2861-2865	IFNs	abstract[181]	giv[181]	_	_
20-27	2866-2867	.	_	_	_	_

#Text=We showed that wtCSFV strongly inhibited expression of poly(I : C)-induced type III IFNs in IPEC-J2 cells and Npro deletion abolished such an inhibitory effect .
21-1	2868-2870	We	person	giv	ana	22-1
21-2	2871-2877	showed	_	_	_	_
21-3	2878-2882	that	_	_	_	_
21-4	2883-2889	wtCSFV	abstract	giv	coref	23-4
21-5	2890-2898	strongly	_	_	_	_
21-6	2899-2908	inhibited	_	_	_	_
21-7	2909-2919	expression	abstract[184]	new[184]	coref	24-12[218_184]
21-8	2920-2922	of	abstract[184]	new[184]	_	_
21-9	2923-2929	poly(I	abstract[184]|abstract	new[184]|new	appos	21-11[186_0]
21-10	2930-2931	:	_	_	_	_
21-11	2932-2942	C)-induced	abstract[186]	giv[186]	coref	22-16[199_186]
21-12	2943-2947	type	abstract[186]	giv[186]	_	_
21-13	2948-2951	III	abstract[187]	giv[187]	coref	22-17[200_187]
21-14	2952-2956	IFNs	abstract[187]	giv[187]	_	_
21-15	2957-2959	in	_	_	_	_
21-16	2960-2967	IPEC-J2	substance|place[189]	giv|giv[189]	coref|coref	23-23|23-23
21-17	2968-2973	cells	place[189]	giv[189]	_	_
21-18	2974-2977	and	place[189]	giv[189]	_	_
21-19	2978-2982	Npro	place[189]|person|event[191]	giv[189]|giv|new[191]	coref|coref	22-5|22-5
21-20	2983-2991	deletion	place[189]|event[191]	giv[189]|new[191]	_	_
21-21	2992-3001	abolished	_	_	_	_
21-22	3002-3006	such	abstract[192]	giv[192]	_	_
21-23	3007-3009	an	abstract[192]	giv[192]	_	_
21-24	3010-3020	inhibitory	abstract[192]	giv[192]	_	_
21-25	3021-3027	effect	abstract[192]	giv[192]	_	_
21-26	3028-3029	.	_	_	_	_

#Text=We further showed that Npro over-expression led to a marked reduction of mRNA transcripts of type III IFNs .
22-1	3030-3032	We	person	giv	ana	32-13
22-2	3033-3040	further	_	_	_	_
22-3	3041-3047	showed	_	_	_	_
22-4	3048-3052	that	_	_	_	_
22-5	3053-3057	Npro	person|abstract[195]	giv|new[195]	coref|coref|coref|coref	23-6[203_195]|23-8|23-6[203_195]|23-8
22-6	3058-3073	over-expression	abstract[195]	new[195]	_	_
22-7	3074-3077	led	_	_	_	_
22-8	3078-3080	to	_	_	_	_
22-9	3081-3082	a	abstract[196]	new[196]	_	_
22-10	3083-3089	marked	abstract[196]	new[196]	_	_
22-11	3090-3099	reduction	abstract[196]	new[196]	_	_
22-12	3100-3102	of	abstract[196]	new[196]	_	_
22-13	3103-3107	mRNA	abstract[196]|object|abstract[198]	new[196]|giv|new[198]	_	_
22-14	3108-3119	transcripts	abstract[196]|abstract[198]	new[196]|new[198]	_	_
22-15	3120-3122	of	abstract[196]|abstract[198]	new[196]|new[198]	_	_
22-16	3123-3127	type	abstract[196]|abstract[198]|abstract[199]	new[196]|new[198]|giv[199]	coref	23-20[0_199]
22-17	3128-3131	III	abstract[196]|abstract[198]|abstract[199]|abstract[200]	new[196]|new[198]|giv[199]|giv[200]	coref	25-4[224_200]
22-18	3132-3136	IFNs	abstract[196]|abstract[198]|abstract[199]|abstract[200]	new[196]|new[198]|giv[199]|giv[200]	_	_
22-19	3137-3138	.	_	_	_	_

#Text=Either infection with wtCSFV or over-expression of Npro also resulted in significant reduction of the IFN-λ3 promoter activity of poly(I : C)-treated IPEC-J2 cells .
23-1	3139-3145	Either	abstract[201]	giv[201]	coref	29-11[257_201]
23-2	3146-3155	infection	abstract[201]	giv[201]	_	_
23-3	3156-3160	with	abstract[201]	giv[201]	_	_
23-4	3161-3167	wtCSFV	abstract[201]|abstract	giv[201]|giv	_	_
23-5	3168-3170	or	abstract[201]	giv[201]	_	_
23-6	3171-3186	over-expression	abstract[201]|abstract[203]	giv[201]|giv[203]	_	_
23-7	3187-3189	of	abstract[201]|abstract[203]	giv[201]|giv[203]	_	_
23-8	3190-3194	Npro	abstract[201]|abstract[203]|organization	giv[201]|giv[203]|giv	coref	24-7[215_0]
23-9	3195-3199	also	_	_	_	_
23-10	3200-3208	resulted	_	_	_	_
23-11	3209-3211	in	_	_	_	_
23-12	3212-3223	significant	abstract[205]	new[205]	_	_
23-13	3224-3233	reduction	abstract[205]	new[205]	_	_
23-14	3234-3236	of	abstract[205]	new[205]	_	_
23-15	3237-3240	the	abstract[205]|abstract[208]	new[205]|new[208]	coref	33-15[292_208]
23-16	3241-3247	IFN-λ3	abstract[205]|place|abstract[208]	new[205]|giv|new[208]	coref	33-15
23-17	3248-3256	promoter	abstract[205]|person|abstract[208]	new[205]|new|new[208]	coref	33-16
23-18	3257-3265	activity	abstract[205]|abstract[208]	new[205]|new[208]	_	_
23-19	3266-3268	of	abstract[205]|abstract[208]	new[205]|new[208]	_	_
23-20	3269-3275	poly(I	abstract[205]|abstract[208]|abstract	new[205]|new[208]|giv	appos	23-22[211_0]
23-21	3276-3277	:	_	_	_	_
23-22	3278-3288	C)-treated	abstract[211]	giv[211]	coref	24-11[0_211]
23-23	3289-3296	IPEC-J2	substance|abstract[211]	giv|giv[211]	coref	32-27
23-24	3297-3302	cells	abstract[211]	giv[211]	_	_
23-25	3303-3304	.	_	_	_	_

#Text=These results demonstrate that CSFV employs its Npro to inhibit type III IFNs expression probably by targeting the regulatory elements involved in transcription of IFN-λs .
24-1	3305-3310	These	abstract[212]	giv[212]	_	_
24-2	3311-3318	results	abstract[212]	giv[212]	_	_
24-3	3319-3330	demonstrate	_	_	_	_
24-4	3331-3335	that	_	_	_	_
24-5	3336-3340	CSFV	object	giv	ana	24-7
24-6	3341-3348	employs	_	_	_	_
24-7	3349-3352	its	object|abstract[215]	giv|giv[215]	_	_
24-8	3353-3357	Npro	abstract[215]	giv[215]	_	_
24-9	3358-3360	to	_	_	_	_
24-10	3361-3368	inhibit	_	_	_	_
24-11	3369-3373	type	abstract	giv	coref	25-3
24-12	3374-3377	III	abstract[218]	giv[218]	_	_
24-13	3378-3382	IFNs	person|abstract[218]	giv|giv[218]	coref	25-13
24-14	3383-3393	expression	abstract[218]	giv[218]	_	_
24-15	3394-3402	probably	abstract[218]	giv[218]	_	_
24-16	3403-3405	by	_	_	_	_
24-17	3406-3415	targeting	_	_	_	_
24-18	3416-3419	the	abstract[219]	new[219]	_	_
24-19	3420-3430	regulatory	abstract[219]	new[219]	_	_
24-20	3431-3439	elements	abstract[219]	new[219]	_	_
24-21	3440-3448	involved	_	_	_	_
24-22	3449-3451	in	_	_	_	_
24-23	3452-3465	transcription	abstract[220]	new[220]	_	_
24-24	3466-3468	of	abstract[220]	new[220]	_	_
24-25	3469-3475	IFN-λs	abstract[220]|abstract	new[220]|new	coref	29-7
24-26	3476-3477	.	_	_	_	_

#Text=Activation of type III IFNs , as the case with type I IFNs , requires IRF3 , IRF7 and NF-κB .
25-1	3478-3488	Activation	abstract[222]	new[222]	_	_
25-2	3489-3491	of	abstract[222]	new[222]	_	_
25-3	3492-3496	type	abstract[222]|abstract	new[222]|giv	coref	25-11
25-4	3497-3500	III	abstract[222]|abstract[224]	new[222]|giv[224]	coref	26-6[233_224]
25-5	3501-3505	IFNs	abstract[222]|abstract[224]	new[222]|giv[224]	_	_
25-6	3506-3507	,	abstract[222]	new[222]	_	_
25-7	3508-3510	as	abstract[222]	new[222]	_	_
25-8	3511-3514	the	abstract[222]	new[222]	_	_
25-9	3515-3519	case	abstract[222]	new[222]	_	_
25-10	3520-3524	with	abstract[222]	new[222]	_	_
25-11	3525-3529	type	abstract[222]|abstract	new[222]|giv	coref	26-5
25-12	3530-3531	I	person	giv	ana	28-20
25-13	3532-3536	IFNs	abstract	giv	coref	28-21
25-14	3537-3538	,	_	_	_	_
25-15	3539-3547	requires	_	_	_	_
25-16	3548-3552	IRF3	abstract	giv	appos	25-18
25-17	3553-3554	,	_	_	_	_
25-18	3555-3559	IRF7	abstract	giv	_	_
25-19	3560-3563	and	_	_	_	_
25-20	3564-3569	NF-κB	abstract	new	_	_
25-21	3570-3571	.	_	_	_	_

#Text=However , expression of type III IFNs does not need all components of the enhanceosome .
26-1	3572-3579	However	_	_	_	_
26-2	3580-3581	,	_	_	_	_
26-3	3582-3592	expression	abstract[231]	new[231]	coref	28-31[251_231]
26-4	3593-3595	of	abstract[231]	new[231]	_	_
26-5	3596-3600	type	abstract[231]|abstract	new[231]|giv	coref	28-19
26-6	3601-3604	III	abstract[231]|abstract[233]	new[231]|giv[233]	coref	28-17[244_233]
26-7	3605-3609	IFNs	abstract[231]|abstract[233]	new[231]|giv[233]	_	_
26-8	3610-3614	does	_	_	_	_
26-9	3615-3618	not	_	_	_	_
26-10	3619-3623	need	_	_	_	_
26-11	3624-3627	all	abstract[234]	new[234]	_	_
26-12	3628-3638	components	abstract[234]	new[234]	_	_
26-13	3639-3641	of	abstract[234]	new[234]	_	_
26-14	3642-3645	the	abstract[234]|abstract[235]	new[234]|new[235]	_	_
26-15	3646-3658	enhanceosome	abstract[234]|abstract[235]	new[234]|new[235]	_	_
26-16	3659-3660	.	_	_	_	_

#Text=IRF1 is a predominant antiviral molecule against many viruses .
27-1	3661-3665	IRF1	substance	giv	coref	27-3[237_0]
27-2	3666-3668	is	_	_	_	_
27-3	3669-3670	a	substance[237]	giv[237]	ana	28-1[0_237]
27-4	3671-3682	predominant	substance[237]	giv[237]	_	_
27-5	3683-3692	antiviral	substance[237]	giv[237]	_	_
27-6	3693-3701	molecule	substance[237]	giv[237]	_	_
27-7	3702-3709	against	substance[237]	giv[237]	_	_
27-8	3710-3714	many	substance[237]|animal[238]	giv[237]|giv[238]	_	_
27-9	3715-3722	viruses	substance[237]|animal[238]	giv[237]|giv[238]	_	_
27-10	3723-3724	.	_	_	_	_

#Text=It is the first identified member of the IRF family , but it does not induce production of type I IFNs . Odendall et al has shown that IRF1 regulates peroxisome-mediated IFN-λ1 expression .
28-1	3725-3727	It	abstract	giv	coref	28-3[240_0]
28-2	3728-3730	is	_	_	_	_
28-3	3731-3734	the	abstract[240]	giv[240]	ana	28-13[0_240]
28-4	3735-3740	first	abstract[240]	giv[240]	_	_
28-5	3741-3751	identified	abstract[240]	giv[240]	_	_
28-6	3752-3758	member	abstract[240]	giv[240]	_	_
28-7	3759-3761	of	abstract[240]	giv[240]	_	_
28-8	3762-3765	the	abstract[240]|abstract[242]	giv[240]|new[242]	_	_
28-9	3766-3769	IRF	abstract[240]|person|abstract[242]	giv[240]|new|new[242]	_	_
28-10	3770-3776	family	abstract[240]|abstract[242]	giv[240]|new[242]	_	_
28-11	3777-3778	,	_	_	_	_
28-12	3779-3782	but	_	_	_	_
28-13	3783-3785	it	abstract	giv	coref	28-29
28-14	3786-3790	does	_	_	_	_
28-15	3791-3794	not	_	_	_	_
28-16	3795-3801	induce	_	_	_	_
28-17	3802-3812	production	abstract[244]	giv[244]	coref	31-8[264_244]
28-18	3813-3815	of	abstract[244]	giv[244]	_	_
28-19	3816-3820	type	abstract[244]|abstract	giv[244]|giv	coref	29-1[252_0]
28-20	3821-3822	I	person	giv	ana	31-17
28-21	3823-3827	IFNs	abstract	giv	_	_
28-22	3828-3829	.	_	_	_	_
28-23	3830-3838	Odendall	person	new	_	_
28-24	3839-3841	et	_	_	_	_
28-25	3842-3844	al	_	_	_	_
28-26	3845-3848	has	_	_	_	_
28-27	3849-3854	shown	_	_	_	_
28-28	3855-3859	that	_	_	_	_
28-29	3860-3864	IRF1	abstract	giv	coref	32-11
28-30	3865-3874	regulates	_	_	_	_
28-31	3875-3894	peroxisome-mediated	abstract[251]	giv[251]	_	_
28-32	3895-3901	IFN-λ1	person|abstract[251]	new|giv[251]	_	_
28-33	3902-3912	expression	abstract[251]	giv[251]	_	_
28-34	3913-3914	.	_	_	_	_

#Text=Epithelial cells have preference of producing IFN-λs over IFN-α/β upon viral infection .
29-1	3915-3925	Epithelial	abstract[252]	giv[252]	coref	30-12[261_252]
29-2	3926-3931	cells	abstract[252]	giv[252]	_	_
29-3	3932-3936	have	_	_	_	_
29-4	3937-3947	preference	abstract	new	_	_
29-5	3948-3950	of	_	_	_	_
29-6	3951-3960	producing	_	_	_	_
29-7	3961-3967	IFN-λs	abstract	giv	coref	33-12[289_0]
29-8	3968-3972	over	_	_	_	_
29-9	3973-3980	IFN-α/β	abstract	new	ana	30-1
29-10	3981-3985	upon	_	_	_	_
29-11	3986-3991	viral	object|abstract[257]	giv|giv[257]	_	_
29-12	3992-4001	infection	abstract[257]	giv[257]	_	_
29-13	4002-4003	.	_	_	_	_

#Text=This may be due to relatively higher expression of peroxisomes in epithelial cells .
30-1	4004-4008	This	abstract	giv	_	_
30-2	4009-4012	may	_	_	_	_
30-3	4013-4015	be	_	_	_	_
30-4	4016-4019	due	_	_	_	_
30-5	4020-4022	to	_	_	_	_
30-6	4023-4033	relatively	abstract[259]	new[259]	coref	32-19[278_259]
30-7	4034-4040	higher	abstract[259]	new[259]	_	_
30-8	4041-4051	expression	abstract[259]	new[259]	_	_
30-9	4052-4054	of	abstract[259]	new[259]	_	_
30-10	4055-4066	peroxisomes	abstract[259]|substance[260]	new[259]|new[260]	_	_
30-11	4067-4069	in	abstract[259]|substance[260]	new[259]|new[260]	_	_
30-12	4070-4080	epithelial	abstract[259]|substance[260]|abstract[261]	new[259]|new[260]|giv[261]	coref	31-7[0_261]
30-13	4081-4086	cells	abstract[259]|substance[260]|abstract[261]	new[259]|new[260]|giv[261]	_	_
30-14	4087-4088	.	_	_	_	_

#Text=Peroxisomal MAVS is known to induce type III IFNs , as opposed to induction of type I IFNs via mitochondrial MAVS .
31-1	4089-4100	Peroxisomal	animal[262]	new[262]	_	_
31-2	4101-4105	MAVS	animal[262]	new[262]	_	_
31-3	4106-4108	is	_	_	_	_
31-4	4109-4114	known	_	_	_	_
31-5	4115-4117	to	_	_	_	_
31-6	4118-4124	induce	_	_	_	_
31-7	4125-4129	type	abstract	giv	coref	31-16
31-8	4130-4133	III	abstract[264]	giv[264]	coref	31-18[268_264]
31-9	4134-4138	IFNs	abstract[264]	giv[264]	_	_
31-10	4139-4140	,	_	_	_	_
31-11	4141-4143	as	_	_	_	_
31-12	4144-4151	opposed	_	_	_	_
31-13	4152-4154	to	_	_	_	_
31-14	4155-4164	induction	event[265]	new[265]	_	_
31-15	4165-4167	of	event[265]	new[265]	_	_
31-16	4168-4172	type	event[265]|abstract	new[265]|giv	coref	32-7
31-17	4173-4174	I	person	giv	_	_
31-18	4175-4179	IFNs	abstract[268]	giv[268]	coref	32-8[273_268]
31-19	4180-4183	via	abstract[268]	giv[268]	_	_
31-20	4184-4197	mitochondrial	abstract[268]|abstract|abstract[270]	giv[268]|new|new[270]	_	_
31-21	4198-4202	MAVS	abstract[268]|abstract[270]	giv[268]|new[270]	_	_
31-22	4203-4204	.	_	_	_	_

#Text=To better understand the regulation of type III IFNs by IRF1 , we attempted to regulate levels of IRF1 expression by overexpression or RNA interference in IPEC-J2 cells .
32-1	4205-4207	To	_	_	_	_
32-2	4208-4214	better	_	_	_	_
32-3	4215-4225	understand	_	_	_	_
32-4	4226-4229	the	abstract[271]	new[271]	_	_
32-5	4230-4240	regulation	abstract[271]	new[271]	_	_
32-6	4241-4243	of	abstract[271]	new[271]	_	_
32-7	4244-4248	type	abstract[271]|abstract	new[271]|giv	coref	32-27[283_0]
32-8	4249-4252	III	abstract[273]	giv[273]	coref	33-34[298_273]
32-9	4253-4257	IFNs	abstract[273]	giv[273]	_	_
32-10	4258-4260	by	_	_	_	_
32-11	4261-4265	IRF1	abstract	giv	coref	32-19
32-12	4266-4267	,	_	_	_	_
32-13	4268-4270	we	person	giv	_	_
32-14	4271-4280	attempted	_	_	_	_
32-15	4281-4283	to	_	_	_	_
32-16	4284-4292	regulate	_	_	_	_
32-17	4293-4299	levels	abstract[276]	new[276]	_	_
32-18	4300-4302	of	abstract[276]	new[276]	_	_
32-19	4303-4307	IRF1	abstract[276]|abstract|abstract[278]	new[276]|giv|giv[278]	coref|coref	33-3|33-3
32-20	4308-4318	expression	abstract[276]|abstract[278]	new[276]|giv[278]	_	_
32-21	4319-4321	by	abstract[276]|abstract[278]	new[276]|giv[278]	_	_
32-22	4322-4336	overexpression	abstract[276]|abstract[278]|abstract	new[276]|giv[278]|new	coref	33-1[284_0]
32-23	4337-4339	or	abstract[276]|abstract[278]	new[276]|giv[278]	_	_
32-24	4340-4343	RNA	abstract[276]|abstract[278]|organization|abstract[281]	new[276]|giv[278]|new|new[281]	_	_
32-25	4344-4356	interference	abstract[276]|abstract[278]|abstract[281]	new[276]|giv[278]|new[281]	_	_
32-26	4357-4359	in	abstract[276]|abstract[278]|abstract[281]	new[276]|giv[278]|new[281]	_	_
32-27	4360-4367	IPEC-J2	abstract[276]|abstract[278]|abstract[281]|substance|abstract[283]	new[276]|giv[278]|new[281]|giv|giv[283]	coref|coref	33-33[0_283]|33-33[0_283]
32-28	4368-4373	cells	abstract[276]|abstract[278]|abstract[281]|abstract[283]	new[276]|giv[278]|new[281]|giv[283]	_	_
32-29	4374-4375	.	_	_	_	_

#Text=Overexpression of IRF1 led to a significant increase of transcription of all IFN-λs and IFN-λ3 promoter activity , while gene silencing showed opposite effects , indicating that IRF1 positively regulates expression of type III IFNs .
33-1	4376-4390	Overexpression	abstract[284]	giv[284]	_	_
33-2	4391-4393	of	abstract[284]	giv[284]	_	_
33-3	4394-4398	IRF1	abstract[284]|object	giv[284]|giv	coref	33-28
33-4	4399-4402	led	_	_	_	_
33-5	4403-4405	to	_	_	_	_
33-6	4406-4407	a	abstract[286]	new[286]	_	_
33-7	4408-4419	significant	abstract[286]	new[286]	_	_
33-8	4420-4428	increase	abstract[286]	new[286]	_	_
33-9	4429-4431	of	abstract[286]	new[286]	_	_
33-10	4432-4445	transcription	abstract[286]|abstract[287]	new[286]|new[287]	_	_
33-11	4446-4448	of	abstract[286]|abstract[287]	new[286]|new[287]	_	_
33-12	4449-4452	all	abstract[286]|abstract[287]|abstract[288]|abstract[289]	new[286]|new[287]|new[288]|giv[289]	_	_
33-13	4453-4459	IFN-λs	abstract[286]|abstract[287]|abstract[288]|abstract[289]	new[286]|new[287]|new[288]|giv[289]	_	_
33-14	4460-4463	and	abstract[286]|abstract[287]|abstract[289]	new[286]|new[287]|giv[289]	_	_
33-15	4464-4470	IFN-λ3	abstract[286]|abstract[287]|abstract[289]|place|abstract[292]	new[286]|new[287]|giv[289]|giv|giv[292]	_	_
33-16	4471-4479	promoter	abstract[286]|abstract[287]|abstract[289]|person|abstract[292]	new[286]|new[287]|giv[289]|giv|giv[292]	_	_
33-17	4480-4488	activity	abstract[286]|abstract[287]|abstract[289]|abstract[292]	new[286]|new[287]|giv[289]|giv[292]	_	_
33-18	4489-4490	,	_	_	_	_
33-19	4491-4496	while	_	_	_	_
33-20	4497-4501	gene	abstract	new	_	_
33-21	4502-4511	silencing	_	_	_	_
33-22	4512-4518	showed	_	_	_	_
33-23	4519-4527	opposite	abstract[294]	new[294]	_	_
33-24	4528-4535	effects	abstract[294]	new[294]	_	_
33-25	4536-4537	,	_	_	_	_
33-26	4538-4548	indicating	_	_	_	_
33-27	4549-4553	that	_	_	_	_
33-28	4554-4558	IRF1	abstract	giv	_	_
33-29	4559-4569	positively	_	_	_	_
33-30	4570-4579	regulates	_	_	_	_
33-31	4580-4590	expression	abstract[296]	giv[296]	_	_
33-32	4591-4593	of	abstract[296]	giv[296]	_	_
33-33	4594-4598	type	abstract[296]|abstract	giv[296]|giv	_	_
33-34	4599-4602	III	abstract[298]	giv[298]	_	_
33-35	4603-4607	IFNs	abstract[298]	giv[298]	_	_
33-36	4608-4609	.	_	_	_	_
